Globe Newswire (Tue, 10-Feb 8:00 AM ET)
Market Chameleon (Mon, 2-Feb 3:14 AM ET)
Globe Newswire (Mon, 2-Feb 8:00 AM ET)
Globe Newswire (Wed, 21-Jan 8:00 AM ET)
Globe Newswire (Mon, 29-Dec 8:00 AM ET)
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Wed, 26-Nov 8:00 AM ET)
neffy’s U.S. Launch Powers ARS Pharmaceuticals’ Revenue Growth, Despite Elevated Marketing Costs
Market Chameleon (Mon, 10-Nov 3:40 AM ET)
Market Chameleon (Fri, 19-Sep 4:32 AM ET)
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ars Pharmaceuticals trades on the NASDAQ stock market under the symbol SPRY.
As of February 12, 2026, SPRY stock price declined to $8.81 with 1,249,095 million shares trading.
SPRY has a beta of 0.24, meaning it tends to be less sensitive to market movements. SPRY has a correlation of 0.00 to the broad based SPY ETF.
SPRY has a market cap of $870.66 million. This is considered a Small Cap stock.
Last quarter Ars Pharmaceuticals reported $33 million in Revenue and -$.52 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.05.
In the last 3 years, SPRY traded as high as $18.90 and as low as $2.55.
The top ETF exchange traded funds that SPRY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
SPRY has underperformed the market in the last year with a price return of -23.7% while the SPY ETF gained +13.8%. However, in the short term, SPRY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +0.5% vs 0.0% return in SPY. But in the last 2 weeks, SPRY shares have been beat by the market, returning -12.4% compared to an SPY return of -2.0%.
SPRY support price is $9.15 and resistance is $9.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRY shares will trade within this expected range on the day.
